The text provides detailed financial data for AbbVie Inc. and its subsidiaries, with key figures for the three and six months ended June 30, 2021, including net revenues, operating costs, earnings before taxes, net earnings, and earnings per share. The data also covers financial aspects such as cash, investments, liabilities, and equity. AbbVie Inc. saw an increase in net revenues and net earnings in 2021 compared to 2020. Additionally, the text discusses various financial aspects of AbbVie, including collaborations, acquisitions, and financial instruments such as derivative instruments, gains and losses recognized in other comprehensive income, and reclassifications of these gains and losses into specific financial categories.
The text provided contains management's discussion and analysis of AbbVie Inc.'s financial condition and results of operations as of June 30, 2021, and December 31, 2020. It outlines the company's strategic objectives, financial results, impact of COVID-19, research and development activities, significant programs, and developments. Additionally, the text covers net revenues by product, gross margin, selling, general and administrative expenses, research and development expenses, income tax expense, cash flows, credit risk, liquidity, capital resources, credit facility, critical accounting policies, and forward-looking statements. It also discusses factors affecting AbbVie's operations, such as risks related to the Allergan acquisition, integration challenges, competition, legal actions, changing laws and regulations, and the impact of public health crises like COVID-19, among others. The company's ability to access capital, credit ratings, and adherence to critical accounting policies are also addressed. AbbVie cautions investors on forward-looking statements and notes that they are subject to various risks and uncertainties.
The text provides information on where to find details about a company's market risk in its Annual Report on Form 10-K for the year ended December 31, 2020. The specific section to refer to for a discussion on market risk is mentioned as Item 7A. Additionally, it indicates that more recent updates for the same information can be found in the 2021 Form 10-Q.
The text discusses the evaluation of AbbVie's disclosure controls and procedures by its Chief Executive Officer and Chief Financial Officer, which were found to be effective in recording, processing, summarizing, and reporting necessary information required by the Securities Exchange Act of 1934. It also mentions that there were no material changes in AbbVie's internal control over financial reporting in the quarter ended June 30, 2021. The limitations of these controls are acknowledged, as they may not be able to prevent or detect all errors and fraud due to various factors like human judgment, resource constraints, and changing conditions. These inherent limitations make it impossible to ensure absolute assurance against misstatements or fraud.
The text provided indicates that information regarding legal proceedings can be found in Note 12 of the Condensed Consolidated Financial Statements.
I apologize for any confusion, but I cannot process or summarize any text that has not been provided to me. Please go ahead and provide me with the text you would like summarized.
The text discusses the unregistered sales of equity securities and the use of proceeds by AbbVie, detailing the total number of shares purchased, average price paid per share, and the maximum number of shares yet to be purchased under the plans or programs for April, May, and June 2021. It highlights the shares repurchased on the open market as per a publicly announced program and those purchased for the AbbVie Employee Stock Purchase Plan participants. Additionally, the text clarifies that the shares purchased did not include those surrendered for tax withholding obligations related to stock-based awards.
I'm here and ready to assist with summarizing the text you have provided. Please go ahead and send me the text.
I am ready to summarize the text for you. Please provide me with the text that you would like me to summarize.
I am sorry, but it appears that there was an error in the message as no text was provided for me to summarize. Could you please resend the text that needs to be summarized?
The text provides information about Exhibits included in a filing under the Securities Exchange Act of 1934 by AbbVie Inc. These Exhibits include certifications by the Chief Executive Officer and Chief Financial Officer, financial statements and notes from their Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and an Interactive Data File. The filing also includes signatures confirming the report's authorization.
